Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 48
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Nat Immunol ; 20(12): 1574-1583, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31745335

RESUMEN

Multiple type I interferons and interferon-γ (IFN-γ) are expressed under physiological conditions and are increased by stress and infections, and in autoinflammatory and autoimmune diseases. Interferons activate the Jak-STAT signaling pathway and induce overlapping patterns of expression, called 'interferon signatures', of canonical interferon-stimulated genes (ISGs) encoding molecules important for antiviral responses, antigen presentation, autoimmunity and inflammation. It has now become clear that interferons also induce an 'interferon epigenomic signature' by activating latent enhancers and 'bookmarking' chromatin, thus reprogramming cell responses to environmental cues. The interferon epigenomic signature affects ISGs and other gene sets, including canonical targets of the transcription factor NF-κB that encode inflammatory molecules, and is involved in the priming of immune cells, tolerance and the training of innate immune memory. Here we review the mechanisms through which interferon signatures and interferon epigenomic signatures are generated, as well as the expression and functional consequences of these signatures in homeostasis and autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis and systemic sclerosis.


Asunto(s)
Enfermedades Autoinmunes/inmunología , Epigénesis Genética/inmunología , Inflamación/inmunología , Interferón Tipo I/metabolismo , Animales , Autoinmunidad , Homeostasis , Humanos , Tolerancia Inmunológica , Interferón Tipo I/genética , Quinasas Janus/metabolismo , Activación de Linfocitos , FN-kappa B/metabolismo , Factores de Transcripción STAT/metabolismo , Transducción de Señal , Transcriptoma
2.
Immunol Rev ; 323(1): 241-256, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38553621

RESUMEN

The discovery of toll-like receptors (TLRs) and the subsequent recognition that endogenous nucleic acids (NAs) could serve as TLR ligands have led to essential insights into mechanisms of healthy immune responses as well as pathogenic mechanisms relevant to systemic autoimmune and inflammatory diseases. In systemic lupus erythematosus, systemic sclerosis, and rheumatoid arthritis, NA-containing immune complexes serve as TLR ligands, with distinct implications depending on the additional immune stimuli available. Plasmacytoid dendritic cells (pDCs), the robust producers of type I interferon (IFN-I), are providing critical insights relevant to TLR-mediated healthy immune responses and tissue repair, as well as generation of inflammation, autoimmunity and fibrosis, processes central to the pathogenesis of many autoimmune diseases. In this review, we describe recent data characterizing the role of platelets and NA-binding chemokines in modulation of TLR signaling in pDCs, as well as implications for how the IFN-I products of pDCs contribute to the generation of inflammation and wound healing responses by monocyte/macrophages. Chemokine modulators of TLR-mediated B cell tolerance mechanisms and interactions between TLR signaling and metabolic pathways are also considered. The modulators of TLR signaling and their contribution to the pathogenesis of systemic autoimmune diseases suggest new opportunities for identification of novel therapeutic targets.


Asunto(s)
Enfermedades Autoinmunes , Autoinmunidad , Células Dendríticas , Inflamación , Interferón Tipo I , Transducción de Señal , Receptores Toll-Like , Humanos , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Animales , Inflamación/inmunología , Receptores Toll-Like/metabolismo , Enfermedades Autoinmunes/inmunología , Interferón Tipo I/metabolismo , Plaquetas/inmunología , Plaquetas/metabolismo , Linfocitos B/inmunología , Linfocitos B/metabolismo , Tolerancia Inmunológica , Inmunomodulación , Quimiocinas/metabolismo
3.
Eur J Immunol ; 54(3): e2350666, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38161237

RESUMEN

Mycobacterium tuberculosis (Mtb) can cause a latent infection that sometimes progresses to clinically active tuberculosis (TB). Type I interferons (IFN-I) have been implicated in initiating the progression from latency to active TB, in part because IFN-I stimulated genes are the earliest genes to be upregulated in patients as they advance to active TB. Plasmacytoid dendritic cells (pDCs) are major producers of IFN-I during viral infections and in response to autoimmune-induced neutrophil extracellular traps. pDCs have also been suggested to be the major producers of IFN-I during Mtb infection of mice and nonhuman primates, but direct evidence has been lacking. Here, we found that Mtb did not stimulate isolated human pDCs to produce IFN-I, but human neutrophils infected with Mtb-activated co-cultured pDCs to do so. Mtb-infected neutrophils produced neutrophil extracellular traps, whose exposed DNA is a well-known mechanism to activate pDCs to secrete IFN-I. We conclude that pDCs contribute to the IFN-I response during Mtb infection by interacting with infected neutrophils which may then promote Mtb pathogenesis.


Asunto(s)
Interferón Tipo I , Mycobacterium tuberculosis , Tuberculosis , Animales , Humanos , Neutrófilos/metabolismo , Interferón Tipo I/metabolismo , Células Dendríticas/metabolismo
4.
J Immunol ; 206(7): 1631-1641, 2021 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-33674446

RESUMEN

Inhibitors of the immunoproteasome (i-20S) have shown promise in mouse models of autoimmune diseases and allograft rejection. In this study, we used a novel inhibitor of the immunoproteasome, PKS3053, that is reversible, noncovalent, tight-binding, and highly selective for the ß5i subunit of the i-20S to evaluate the role that i-20S plays in regulating immune responses in vitro and in vivo. In contrast to irreversible, less-selective inhibitors, PKS3053 did not kill any of the primary human cell types tested, including plasmacytoid dendritic cells, conventional dendritic cells, macrophages, and T cells, all of which expressed genes encoding both the constitutive proteasome (c-20S) and i-20S. PKS3053 reduced TLR-dependent activation of plasmacytoid dendritic cells, decreasing their maturation and IFN-α response and reducing their ability to activate allogenic T cells. In addition, PKS3053 reduced T cell proliferation directly and inhibited TLR-mediated activation of conventional dendritic cells and macrophages. In a mouse model of skin injury that shares some features of cutaneous lupus erythematosus, blocking i-20S decreased inflammation, cellular infiltration, and tissue damage. We conclude that the immunoproteasome is involved in the activation of innate and adaptive immune cells, that their activation can be suppressed with an i-20S inhibitor without killing them, and that selective inhibition of ß5i holds promise as a potential therapy for inflammatory skin diseases such as psoriasis, cutaneous lupus erythematosus, and systemic sclerosis.


Asunto(s)
Células Dendríticas/inmunología , Inflamación/tratamiento farmacológico , Lupus Eritematoso Cutáneo/tratamiento farmacológico , Macrófagos/inmunología , Inhibidores de Proteasoma/uso terapéutico , Piel/patología , Linfocitos T/inmunología , Animales , Movimiento Celular , Células Cultivadas , Citotoxicidad Inmunológica , Células Dendríticas/efectos de los fármacos , Modelos Animales de Enfermedad , Femenino , Humanos , Activación de Linfocitos , Macrófagos/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Complejo de la Endopetidasa Proteasomal/metabolismo , Linfocitos T/efectos de los fármacos
5.
Curr Opin Rheumatol ; 31(6): 569-575, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31436583

RESUMEN

PURPOSE OF REVIEW: The role of type I IFNs (IFN-I) in the promotion of autoimmunity has been well established. However, its role in the skin fibrosis of systemic sclerosis (SSc) is less clear. IFN-I can participate to tissue repair, and, here, we will consider the extent to which IFN-I's role in SSc skin fibrosis may reflect in part IFN-I functions during wound healing. RECENT FINDINGS: Studies are beginning to delineate whether IFN-I has a protective or pathogenic role and how IFN-I affects tissue biology. Recent support for a pathogenic role came from a study depleting plasmacytoid dendritic cells during bleomycin-induced skin fibrosis. The depletion reduced the bleomycin-induced IFN-I-stimulated transcripts and both prevented and reversed fibrosis. Additionally, two recent articles, one identifying SSc endothelial cell injury markers and one showing repressed IFN signaling in SSc keratinocytes, suggest the possibility of unbalanced IFN-I activities on distinct cells types. SUMMARY: Recent results support a pathogenic role for IFN-I in skin fibrosis, and recent studies along with others suggest a scenario whereby SSc skin damage results from too much IFN-I-activity driving vasculopathy in combination with too little IFN-I-mediated epidermal integrity and antifibrotic fibroblast phenotype.


Asunto(s)
Células Dendríticas/inmunología , Inmunidad Innata , Interferón Tipo I/metabolismo , Esclerodermia Sistémica/inmunología , Piel/metabolismo , Animales , Fibroblastos/inmunología , Fibroblastos/patología , Humanos , Esclerodermia Sistémica/metabolismo , Transducción de Señal , Piel/patología
6.
Proc Natl Acad Sci U S A ; 113(52): E8425-E8432, 2016 12 27.
Artículo en Inglés | MEDLINE | ID: mdl-27956634

RESUMEN

Constitutive proteasomes (c-20S) are ubiquitously expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. An isoform of proteasome, the immunoproteasome (i-20S), is highly expressed in human T cells, dendritic cells (DCs), and B cells, suggesting that it could be a potential target for inflammatory diseases, including those involving autoimmunity and alloimmunity. Here, we describe DPLG3, a rationally designed, noncovalent inhibitor of the immunoproteasome chymotryptic subunit ß5i that has thousands-fold selectivity over constitutive ß5c. DPLG3 suppressed cytokine release from blood mononuclear cells and the activation of DCs and T cells, diminished accumulation of effector T cells, promoted expression of exhaustion and coinhibitory markers on T cells, and synergized with CTLA4-Ig to promote long-term acceptance of cardiac allografts across a major histocompatibility barrier. These findings demonstrate the potential value of using brief posttransplant immunoproteasome inhibition to entrain a long-term response favorable to allograft survival as part of an immunomodulatory regimen that is neither broadly immunosuppressive nor toxic.


Asunto(s)
Supervivencia de Injerto , Trasplante de Corazón/métodos , Inmunosupresores/farmacología , Complejo de la Endopetidasa Proteasomal/metabolismo , Inhibidores de Proteasoma/farmacología , Animales , Línea Celular Tumoral , Proliferación Celular , Citocinas/inmunología , Células Dendríticas/citología , Células Dendríticas/inmunología , Células Hep G2 , Humanos , Memoria Inmunológica , Leucocitos Mononucleares/citología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Linfocitos T/inmunología
7.
Annu Rev Med ; 67: 323-36, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26526766

RESUMEN

An important concept in immunology is the classification of immune responses as either innate or adaptive, based on whether the antigen receptors are encoded in the germline or generated somatically by gene rearrangement. The innate immune system is an ancient mode of immunity, and by being a first layer in our defense against infectious agents, it is essential for our ability to develop rapid and sustained responses to pathogens. We discuss the importance of nucleic acid recognition by the innate immune system to mounting an appropriate immune response to pathogens and also how inflammation driven by uncontrolled recognition of self-nucleic acids can lead to autoimmune diseases. We also summarize current efforts to either harness the immune system using agonists of nucleic acid-specific innate sensors or, on the contrary, by using inhibitors in autoimmune situations.


Asunto(s)
Autoinmunidad/inmunología , Inmunidad Innata , Inflamación/inmunología , Ácidos Nucleicos/inmunología , Receptores Toll-Like/agonistas , Receptores Toll-Like/antagonistas & inhibidores , Adyuvantes Inmunológicos/uso terapéutico , Aminoquinolinas/uso terapéutico , Animales , Citosol/inmunología , ADN Viral/inmunología , Endosomas/inmunología , Humanos , Imiquimod , Inflamación/metabolismo , Lupus Eritematoso Sistémico/inmunología , Psoriasis/inmunología , Transducción de Señal , Receptores Toll-Like/inmunología , Virosis/inmunología
8.
Nature ; 465(7300): 937-41, 2010 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-20559388

RESUMEN

Glucocorticoids are widely used to treat patients with autoimmune diseases such as systemic lupus erythematosus (SLE). However, regimens used to treat many such conditions cannot maintain disease control in the majority of SLE patients and more aggressive approaches such as high-dose methylprednisolone pulse therapy are used to provide transient reductions in disease activity. The primary anti-inflammatory mechanism of glucocorticoids is thought to be NF-kappaB inhibition. Recognition of self nucleic acids by toll-like receptors TLR7 and TLR9 on B cells and plasmacytoid dendritic cells (PDCs) is an important step in the pathogenesis of SLE, promoting anti-nuclear antibodies and the production of type I interferon (IFN), both correlated with the severity of disease. Following their activation by self-nucleic acid-associated immune complexes, PDCs migrate to the tissues. We demonstrate, in vitro and in vivo, that stimulation of PDCs through TLR7 and 9 can account for the reduced activity of glucocorticoids to inhibit the IFN pathway in SLE patients and in two lupus-prone mouse strains. The triggering of PDCs through TLR7 and 9 by nucleic acid-containing immune complexes or by synthetic ligands activates the NF-kappaB pathway essential for PDC survival. Glucocorticoids do not affect NF-kappaB activation in PDCs, preventing glucocorticoid induction of PDC death and the consequent reduction of systemic IFN-alpha levels. These findings unveil a new role for self nucleic acid recognition by TLRs and indicate that inhibitors of TLR7 and 9 signalling could prove to be effective corticosteroid-sparing drugs.


Asunto(s)
Células Dendríticas/efectos de los fármacos , Glucocorticoides/farmacología , Lupus Eritematoso Sistémico/fisiopatología , Ácidos Nucleicos/inmunología , Receptor Toll-Like 7/inmunología , Receptor Toll-Like 9/inmunología , Adolescente , Animales , Autoanticuerpos/inmunología , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Niño , Modelos Animales de Enfermedad , Femenino , Humanos , Interferón-alfa/inmunología , Interferones/inmunología , Masculino , Glicoproteínas de Membrana/inmunología , Ratones , Ratones Endogámicos C57BL , FN-kappa B/inmunología , Regulación hacia Arriba
9.
Eur J Immunol ; 44(4): 1130-6, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24375473

RESUMEN

Plasmacytoid dendritic cells (PDCs) represent a key cell type for both innate and adaptive immunity. PDCs express both TLR7 and TLR9 and the recognition of nucleic acids by these two receptors triggers the production of a large amount of type-I IFN and the induction of PDC maturation into APCs. This unique feature of PDCs is at the basis of clinical development of both TLR7 and TLR9 agonists for infectious diseases, allergy, cancer, and asthma. However, TLR7 and TLR9 recognition of self-nucleic acids is linked to many autoimmune diseases including lupus, and a better understanding of the signaling pathways of these two receptors in PDCs is thus important. We have identified Bruton's tyrosine kinase (Btk) as an important player for TLR9 but not TLR7 signaling in human PDCs. Blocking Btk using a specific inhibitor leads to the reduction of all TLR9-induced responses in PDCs, including cytokine production and expression of costimulatory molecules, while this has no impact on the TLR7 response. This identifies Btk as a key molecule in TLR9 signaling in PDCs and is the first demonstration that the TLR7 and TLR9 pathways can be dissociated in human PDCs.


Asunto(s)
Células Dendríticas/inmunología , Proteínas Tirosina Quinasas/inmunología , Transducción de Señal/inmunología , Receptor Toll-Like 7/inmunología , Receptor Toll-Like 9/inmunología , Agammaglobulinemia Tirosina Quinasa , Células Cultivadas , Quimiocina CCL4/inmunología , Quimiocina CCL4/metabolismo , Quimiocina CXCL10/inmunología , Quimiocina CXCL10/metabolismo , Células Dendríticas/efectos de los fármacos , Células Dendríticas/metabolismo , Relación Dosis-Respuesta a Droga , Citometría de Flujo , Humanos , Factor 7 Regulador del Interferón/inmunología , Factor 7 Regulador del Interferón/metabolismo , Interferón-alfa/inmunología , Interferón-alfa/metabolismo , Isoquinolinas/farmacología , FN-kappa B/inmunología , FN-kappa B/metabolismo , Oligodesoxirribonucleótidos/farmacología , Análisis de Secuencia por Matrices de Oligonucleótidos , Fosforilación , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Proteínas Tirosina Quinasas/metabolismo , Transducción de Señal/efectos de los fármacos , Receptor Toll-Like 7/agonistas , Receptor Toll-Like 7/metabolismo , Receptor Toll-Like 9/agonistas , Receptor Toll-Like 9/metabolismo , Transcriptoma/efectos de los fármacos , Transcriptoma/genética , Transcriptoma/inmunología , Factor de Necrosis Tumoral alfa/inmunología , Factor de Necrosis Tumoral alfa/metabolismo
10.
PLoS Pathog ; 9(7): e1003530, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23935491

RESUMEN

Persistent production of type I interferon (IFN) by activated plasmacytoid dendritic cells (pDC) is a leading model to explain chronic immune activation in human immunodeficiency virus (HIV) infection but direct evidence for this is lacking. We used a dual antagonist of Toll-like receptor (TLR) 7 and TLR9 to selectively inhibit responses of pDC but not other mononuclear phagocytes to viral RNA prior to and for 8 weeks following pathogenic simian immunodeficiency virus (SIV) infection of rhesus macaques. We show that pDC are major but not exclusive producers of IFN-α that rapidly become unresponsive to virus stimulation following SIV infection, whereas myeloid DC gain the capacity to produce IFN-α, albeit at low levels. pDC mediate a marked but transient IFN-α response in lymph nodes during the acute phase that is blocked by administration of TLR7 and TLR9 antagonist without impacting pDC recruitment. TLR7 and TLR9 blockade did not impact virus load or the acute IFN-α response in plasma and had minimal effect on expression of IFN-stimulated genes in both blood and lymph node. TLR7 and TLR9 blockade did not prevent activation of memory CD4+ and CD8+ T cells in blood or lymph node but led to significant increases in proliferation of both subsets in blood following SIV infection. Our findings reveal that virus-mediated activation of pDC through TLR7 and TLR9 contributes to substantial but transient IFN-α production following pathogenic SIV infection. However, the data indicate that pDC activation and IFN-α production are unlikely to be major factors in driving immune activation in early infection. Based on these findings therapeutic strategies aimed at blocking pDC function and IFN-α production may not reduce HIV-associated immunopathology.


Asunto(s)
Antirretrovirales/uso terapéutico , Células Dendríticas/efectos de los fármacos , Interferón-alfa/biosíntesis , Síndrome de Inmunodeficiencia Adquirida del Simio/tratamiento farmacológico , Virus de la Inmunodeficiencia de los Simios/efectos de los fármacos , Receptor Toll-Like 7/antagonistas & inhibidores , Receptor Toll-Like 9/antagonistas & inhibidores , Animales , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/patología , Linfocitos T CD8-positivos/efectos de los fármacos , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/patología , Proliferación Celular/efectos de los fármacos , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Células Dendríticas/virología , Regulación Viral de la Expresión Génica/efectos de los fármacos , Interferón-alfa/sangre , Ganglios Linfáticos/efectos de los fármacos , Ganglios Linfáticos/inmunología , Ganglios Linfáticos/metabolismo , Ganglios Linfáticos/virología , Macaca mulatta , Terapia Molecular Dirigida , Oligonucleótidos Fosforotioatos/uso terapéutico , Síndrome de Inmunodeficiencia Adquirida del Simio/sangre , Síndrome de Inmunodeficiencia Adquirida del Simio/metabolismo , Síndrome de Inmunodeficiencia Adquirida del Simio/virología , Virus de la Inmunodeficiencia de los Simios/inmunología , Virus de la Inmunodeficiencia de los Simios/fisiología , Receptor Toll-Like 7/metabolismo , Receptor Toll-Like 9/metabolismo , Factor de Necrosis Tumoral alfa/biosíntesis , Factor de Necrosis Tumoral alfa/sangre , Carga Viral/efectos de los fármacos , Proteínas Virales/sangre , Proteínas Virales/genética , Proteínas Virales/metabolismo , Activación Viral/efectos de los fármacos
11.
Nat Med ; 13(5): 552-9, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17479101

RESUMEN

The identification of the antigen recognition receptors for innate immunity, most notably the Toll-like receptors, has sparked great interest in therapeutic manipulation of the innate immune system. Toll-like receptor agonists are being developed for the treatment of cancer, allergies and viral infections, and as adjuvants for potent new vaccines to prevent or treat cancer and infectious diseases. As recognition grows of the role of inappropriate Toll-like receptor stimulation in inflammation and autoimmunity, significant efforts have begun to develop antagonists to Toll-like receptors as well.


Asunto(s)
Inmunidad Innata , Receptores Toll-Like/inmunología , Animales , Antígenos/inmunología , Autoinmunidad , Humanos , Hipersensibilidad/inmunología , Inflamación/inmunología , Modelos Inmunológicos , Neoplasias/inmunología , Receptores Toll-Like/agonistas , Receptores Toll-Like/antagonistas & inhibidores , Receptores Toll-Like/genética , Virosis/inmunología
12.
Nat Med ; 13(9): 1050-9, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17704786

RESUMEN

Conventional cancer treatments rely on radiotherapy and chemotherapy. Such treatments supposedly mediate their effects via the direct elimination of tumor cells. Here we show that the success of some protocols for anticancer therapy depends on innate and adaptive antitumor immune responses. We describe in both mice and humans a previously unrecognized pathway for the activation of tumor antigen-specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs). During chemotherapy or radiotherapy, DCs require signaling through TLR4 and its adaptor MyD88 for efficient processing and cross-presentation of antigen from dying tumor cells. Patients with breast cancer who carry a TLR4 loss-of-function allele relapse more quickly after radiotherapy and chemotherapy than those carrying the normal TLR4 allele. These results delineate a clinically relevant immunoadjuvant pathway triggered by tumor cell death.


Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias/tratamiento farmacológico , Neoplasias/radioterapia , Receptor Toll-Like 4/inmunología , Animales , Neoplasias Óseas/tratamiento farmacológico , Línea Celular Tumoral , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/radioterapia , Modelos Animales de Enfermedad , Humanos , Ratones , Ratones Endogámicos BALB C , Compuestos Organoplatinos/uso terapéutico , Osteosarcoma/tratamiento farmacológico , Piridinas/uso terapéutico
13.
J Exp Med ; 204(10): 2407-22, 2007 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-17893200

RESUMEN

Human interleukin (IL) 1 receptor-associated kinase 4 (IRAK-4) deficiency is a recently discovered primary immunodeficiency that impairs Toll/IL-1R immunity, except for the Toll-like receptor (TLR) 3- and TLR4-interferon (IFN)-alpha/beta pathways. The clinical and immunological phenotype remains largely unknown. We diagnosed up to 28 patients with IRAK-4 deficiency, tested blood TLR responses for individual leukocyte subsets, and TLR responses for multiple cytokines. The patients' peripheral blood mononuclear cells (PBMCs) did not induce the 11 non-IFN cytokines tested upon activation with TLR agonists other than the nonspecific TLR3 agonist poly(I:C). The patients' individual cell subsets from both myeloid (granulocytes, monocytes, monocyte-derived dendritic cells [MDDCs], myeloid DCs [MDCs], and plasmacytoid DCs) and lymphoid (B, T, and NK cells) lineages did not respond to the TLR agonists that stimulated control cells, with the exception of residual responses to poly(I:C) and lipopolysaccharide in MDCs and MDDCs. Most patients (22 out of 28; 79%) suffered from invasive pneumococcal disease, which was often recurrent (13 out of 22; 59%). Other infections were rare, with the exception of severe staphylococcal disease (9 out of 28; 32%). Almost half of the patients died (12 out of 28; 43%). No death and no invasive infection occurred in patients older than 8 and 14 yr, respectively. The IRAK-4-dependent TLRs and IL-1Rs are therefore vital for childhood immunity to pyogenic bacteria, particularly Streptococcus pneumoniae. Conversely, IRAK-4-dependent human TLRs appear to play a redundant role in protective immunity to most infections, at most limited to childhood immunity to some pyogenic bacteria.


Asunto(s)
Infecciones Bacterianas/inmunología , Infecciones Bacterianas/metabolismo , Quinasas Asociadas a Receptores de Interleucina-1/deficiencia , Quinasas Asociadas a Receptores de Interleucina-1/metabolismo , Receptores Toll-Like/metabolismo , Adolescente , Adulto , Infecciones Bacterianas/patología , Diferenciación Celular/inmunología , Células Cultivadas , Niño , Preescolar , Citocinas/biosíntesis , Citocinas/metabolismo , Femenino , Regulación de la Expresión Génica , Humanos , Lactante , Quinasas Asociadas a Receptores de Interleucina-1/genética , Leucocitos/citología , Leucocitos/inmunología , Leucocitos/metabolismo , Masculino , Mutación/genética , Células Mieloides/inmunología , Células Mieloides/metabolismo , Linaje , Receptores Toll-Like/agonistas
14.
J Leukoc Biol ; 114(6): 615-629, 2023 11 24.
Artículo en Inglés | MEDLINE | ID: mdl-37648661

RESUMEN

Regulation of the profile and magnitude of toll-like receptor (TLR) responses is important for effective host defense against infections while minimizing inflammatory toxicity. The chemokine CXCL4 regulates the TLR8 response to amplify inflammatory gene and inflammasome activation while attenuating the interferon (IFN) response in primary monocytes. In this study, we describe an unexpected role for the kinase RIPK3 in suppressing the CXCL4 + TLR8-induced IFN response and providing signal 2 to activate the NLRP3 inflammasome and interleukin (IL)-1 production in primary human monocytes. RIPK3 also amplifies induction of inflammatory genes such as TNF, IL6, and IL1B while suppressing IL12B. Mechanistically, RIPK3 inhibits STAT1 activation and activates PI3K-Akt-dependent and XBP1- and NRF2-mediated stress responses to regulate downstream genes in a dichotomous manner. These findings identify new functions for RIPK3 in modulating TLR responses and provide potential mechanisms by which RIPK3 plays roles in inflammatory diseases and suggest targeting RIPK3 and XBP1- and NRF2-mediated stress responses as therapeutic strategies to suppress inflammation while preserving the IFN response for host defense.


Asunto(s)
Inflamasomas , Monocitos , Humanos , Monocitos/metabolismo , Inflamasomas/metabolismo , Proteína con Dominio Pirina 3 de la Familia NLR , Receptor Toll-Like 8 , Factor 2 Relacionado con NF-E2 , Fosfatidilinositol 3-Quinasas , Receptores Toll-Like/metabolismo , Interleucina-1beta/metabolismo , Proteína Serina-Treonina Quinasas de Interacción con Receptores/genética , Proteína Serina-Treonina Quinasas de Interacción con Receptores/metabolismo
15.
Biol Sex Differ ; 14(1): 60, 2023 09 18.
Artículo en Inglés | MEDLINE | ID: mdl-37723501

RESUMEN

BACKGROUND: Human endosomal Toll-like receptors TLR7 and TLR8 recognize self and non-self RNA ligands, and are important mediators of innate immunity and autoimmune pathogenesis. TLR7 and TLR8 are, respectively, encoded by adjacent X-linked genes. We previously established that TLR7 evades X chromosome inactivation (XCI) in female immune cells. Whether TLR8 also evades XCI, however, has not yet been explored. METHOD: In the current study, we used RNA fluorescence in situ hybridization (RNA FISH) to directly visualize, on a single-cell basis, primary transcripts of TLR7 and TLR8 relative to X chromosome territories in CD14+ monocytes and CD4+ T lymphocytes from women, Klinefelter syndrome (KS) men, and euploid men. To assign X chromosome territories in cells lacking robust expression of a XIST compartment, we designed probes specific for X-linked genes that do not escape XCI and therefore robustly label the active X chromosome. We also assessed whether XCI escape of TLR8 was associated with sexual dimorphism in TLR8 protein expression by western blot and flow cytometry. RESULTS: Using RNA FISH, we show that TLR8, like TLR7, evades XCI in immune cells, and that cells harboring simultaneously TLR7 and TLR8 transcript foci are more frequent in women and KS men than in euploid men, resulting in a sevenfold difference in frequency. This transcriptional bias was again observable when comparing the single X of XY males with the active X of cells from females or KS males. Interestingly, TLR8 protein expression was significantly higher in female mononuclear blood cells, including all monocyte subsets, than in male cells. CONCLUSIONS: TLR8, mirroring TLR7, escapes XCI in human monocytes and CD4+ T cells. Co-dependent transcription from the active X chromosome and escape from XCI could both contribute to higher TLR8 protein abundance in female cells, which may have implications for the response to viruses and bacteria, and the risk of developing inflammatory and autoimmune diseases.


Human endosomal Toll-like receptors TLR7 and TLR8, encoded by two adjacent X-linked genes, recognize self and non-self RNA ligands, and are important mediators of innate immunity and autoimmune pathogenesis. We previously reported that TLR7 evades X chromosome inactivation (XCI) in female immune cells, correlating with enhanced functional properties in B cells harboring biallelic expression of this gene. Here, we conducted a comprehensive single-cell resolution analysis of the transcriptional regulation of both TLR7 and TLR8, in CD14+ monocytes and CD4+ T lymphocytes. We unequivocally demonstrated that TLR8, like TLR7, escapes XCI in immune cells from female and Klinefelter syndrome males. When we analyzed TLR7 and TLR8 transcripts together, cells from women and KS men exhibited higher frequencies of cells co-transcribing the two genes. Surprisingly, these differences were attributable not only to the ability of TLR7 and TLR8 to be expressed on the Xi, but also to the joint transcriptional behavior of the TLR7­TLR8 gene pair on the active X chromosome specifically. This contrasted with a striking pattern of mutually exclusive transcription on the single X of euploid men. Corroborating our RNA FISH results, we found higher TLR8 protein expression in female than in male leukocytes, including all monocyte subpopulations. In summary, our data suggest that sex-biased co-regulation of the Toll-like receptor locus and XCI escape of TLR8 contribute to the sexual dimorphism in TLR8 expression, which may have important consequences for the functional make-up of monocyte and T cell populations.


Asunto(s)
Monocitos , Inactivación del Cromosoma X , Humanos , Femenino , Masculino , Receptor Toll-Like 8/genética , Linfocitos T , Hibridación Fluorescente in Situ , Receptor Toll-Like 7/genética , Linfocitos T CD4-Positivos
16.
J Exp Med ; 220(12)2023 12 04.
Artículo en Inglés | MEDLINE | ID: mdl-37773045

RESUMEN

Central B cell tolerance is believed to be regulated by B cell receptor signaling induced by the recognition of self-antigens in immature B cells. Using humanized mice with defective MyD88, TLR7, or TLR9 expression, we demonstrate that TLR9/MYD88 are required for central B cell tolerance and the removal of developing autoreactive clones. We also show that CXCL4, a chemokine involved in systemic sclerosis (SSc), abrogates TLR9 function in B cells by sequestering TLR9 ligands away from the endosomal compartments where this receptor resides. The in vivo production of CXCL4 thereby impedes both TLR9 responses in B cells and the establishment of central B cell tolerance. We conclude that TLR9 plays an essential early tolerogenic function required for the establishment of central B cell tolerance and that correcting defective TLR9 function in B cells from SSc patients may represent a novel therapeutic strategy to restore B cell tolerance.


Asunto(s)
Factor Plaquetario 4 , Esclerodermia Sistémica , Receptor Toll-Like 9 , Animales , Humanos , Ratones , Linfocitos B , Ligandos , Factor 88 de Diferenciación Mieloide/metabolismo , Factor Plaquetario 4/metabolismo , Esclerodermia Sistémica/metabolismo , Receptor Toll-Like 7 , Receptor Toll-Like 9/metabolismo
17.
J Biol Chem ; 286(35): 30444-30454, 2011 Sep 02.
Artículo en Inglés | MEDLINE | ID: mdl-21730058

RESUMEN

Autoimmune associated congenital heart block (CHB) may result from pathogenic cross-talk between inflammatory and profibrosing pathways. Incubation of macrophages with immune complexes (IC) composed of Ro60, a target of the pathologic maternal autoantibodies necessary for CHB, hY3 ssRNA, and affinity-purified anti-Ro60 antibody induces the Toll-like receptor 7 (TLR7)-dependent generation of supernatants that provoke a fibrosing phenotype in human fetal cardiac fibroblasts. We show herein that these cells are a major source of TGFß and that endothelin-1 (ET-1) is one of the key components responsible for the profibrosing effects generated by stimulated macrophages. Supernatants from macrophages incubated with IC induced the fibroblast secretion of TGFß, which was inhibited by treating the macrophages with an antagonist of TLR7. Under the same conditions, the induced fibroblast secretion of TGFß was decreased by inhibitors of the ET-1 receptors ETa or ETb or by an anti-ET-1 antibody but not by an isotype control. Exogenous ET-1 induced a profibrosing phenotype, whereas fibroblasts transfected with either ETa or ETb siRNA were unresponsive to the profibrosing effects of the IC-generated macrophage supernatants. Immunohistochemistry of the hearts from two fetuses dying with CHB revealed the presence of ET-1-producing mononuclear cells in the septal region in areas of calcification and fibrosis. In conclusion, these data support a novel role of ET-1 in linking TLR7 inflammatory signaling to subsequent fibrosis and provide new insight in considering therapeutics for CHB.


Asunto(s)
Anticuerpos/química , Endotelina-1/fisiología , Fibrosis/metabolismo , Bloqueo Cardíaco/congénito , Inflamación , Ribonucleoproteínas/química , Receptor Toll-Like 7/metabolismo , Autoinmunidad , Femenino , Fibroblastos/metabolismo , Citometría de Flujo , Bloqueo Cardíaco/metabolismo , Humanos , Leucocitos Mononucleares/citología , Macrófagos/citología , Macrófagos/metabolismo , Factor de Crecimiento Transformador beta/metabolismo
18.
J Exp Med ; 203(8): 1999-2008, 2006 Aug 07.
Artículo en Inglés | MEDLINE | ID: mdl-16864658

RESUMEN

Human plasmacytoid dendritic cells (PDCs) can produce interferon (IFN)-alpha and/or mature and participate in the adaptive immune response. Three classes of CpG oligonucleotide ligands for Toll-like receptor (TLR)9 can be distinguished by different sequence motifs and different abilities to stimulate IFN-alpha production and maturation of PDCs. We show that the nature of the PDC response is determined by the higher order structure and endosomal location of the CpG oligonucleotide. Activation of TLR9 by the multimeric CpG-A occurs in transferrin receptor (TfR)-positive endosomes and leads exclusively to IFN-alpha production, whereas monomeric CpG-B oligonucleotides localize to lysosome-associated membrane protein (LAMP)-1-positive endosomes and promote maturation of PDCs. However, CpG-B, when complexed into microparticles, localizes in TfR-positive endosomes and induces IFN-alpha from PDCs, whereas monomeric forms of CpG-A localize to LAMP-1-positive endosomes accompanied by the loss of IFN-alpha production and a gain in PDC maturation activity. CpG-C sequences, which induce both IFN-alpha and maturation of PDCs, are distributed in both type of endosomes. Encapsulation of CpG-C in liposomes stable above pH 5.75 completely abrogated the IFN-alpha response while increasing PDC maturation. This establishes that the primary determinant of TLR9 signaling is not valency but endosomal location and demonstrates a strict compartmentalization of the biological response to TLR9 activation in PDCs.


Asunto(s)
Células Dendríticas/inmunología , Receptor Toll-Like 9/inmunología , Transporte Biológico , Células Dendríticas/citología , Humanos , Concentración de Iones de Hidrógeno , Interferón-alfa/biosíntesis , Ligandos , Liposomas/metabolismo , Activación de Linfocitos/inmunología , Conformación de Ácido Nucleico , Oligodesoxirribonucleótidos/química , Oligodesoxirribonucleótidos/inmunología , Linfocitos T/citología , Linfocitos T/inmunología , Receptor Toll-Like 9/metabolismo
19.
J Immunol ; 184(4): 2148-55, 2010 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-20089705

RESUMEN

Activation of TLR by ssRNA after FcgammaR-mediated phagocytosis of immune complexes (IC) may be relevant in autoimmune-associated congenital heart block (CHB) where the obligate factor is a maternal anti-SSA/Ro Ab and the fetal factors, protein/RNA on an apoptotic cardiocyte and infiltrating macrophages. This study addressed the hypothesis that Ro60-associated ssRNAs link macrophage activation to fibrosis via TLR engagement. Both macrophage transfection with noncoding ssRNA that bind Ro60 and an IC generated by incubation of Ro60-ssRNA with an IgG fraction from a CHB mother or affinity purified anti-Ro60 significantly increased TNF-alpha secretion, an effect not observed using control RNAs or normal IgG. Dependence on TLR was supported by the significant inhibition of TNF-alpha release by IRS661 and chloroquine. The requirement for FcgammaRIIIa-mediated delivery was provided by inhibition with an anti-CD16a Ab. Fibrosis markers were noticeably increased in fetal cardiac fibroblasts after incubation with supernatants generated from macrophages transfected with ssRNA or incubated with the IC. Supernatants generated from macrophages with ssRNA in the presence of IRS661 or chloroquine did not cause fibrosis. In a CHB heart, but not a healthy heart, TLR7 immunostaining was localized to a region near the atrioventricular groove at a site enriched in mononuclear cells and fibrosis. These data support a novel injury model in CHB, whereby endogenous ligand, Ro60-associated ssRNA, forges a nexus between TLR ligation and fibrosis instigated by binding of anti-Ro Abs to the target protein likely accessible via apoptosis.


Asunto(s)
Anticuerpos Antinucleares/metabolismo , Autoantígenos/metabolismo , Enfermedades Fetales/inmunología , Bloqueo Cardíaco/inmunología , Mediadores de Inflamación/metabolismo , Miocitos Cardíacos/inmunología , ARN Citoplasmático Pequeño/metabolismo , Proteínas de Unión al ARN/metabolismo , Ribonucleoproteínas/metabolismo , Receptores Toll-Like/metabolismo , Anticuerpos Antinucleares/biosíntesis , Anticuerpos Antinucleares/genética , Autoantígenos/genética , Autoantígenos/inmunología , Sitios de Unión de Anticuerpos/genética , Células Cultivadas , Técnicas de Cocultivo , Femenino , Enfermedades Fetales/metabolismo , Enfermedades Fetales/patología , Fibroblastos/inmunología , Fibroblastos/metabolismo , Fibroblastos/patología , Fibrosis , Bloqueo Cardíaco/congénito , Bloqueo Cardíaco/patología , Humanos , Mediadores de Inflamación/inmunología , Ligandos , Intercambio Materno-Fetal/genética , Intercambio Materno-Fetal/inmunología , Miocitos Cardíacos/metabolismo , Miocitos Cardíacos/patología , Embarazo , ARN Citoplasmático Pequeño/genética , ARN Citoplasmático Pequeño/inmunología , Proteínas de Unión al ARN/genética , Proteínas de Unión al ARN/inmunología , Ribonucleoproteínas/genética , Ribonucleoproteínas/inmunología , Transducción de Señal/genética , Transducción de Señal/inmunología , Receptor Toll-Like 7/antagonistas & inhibidores , Receptor Toll-Like 7/metabolismo , Receptor Toll-Like 8/antagonistas & inhibidores , Receptor Toll-Like 8/metabolismo , Receptores Toll-Like/antagonistas & inhibidores
20.
Immunol Rev ; 223: 271-83, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18613842

RESUMEN

SUMMARY: The innate immune system is a critical element of protection from invading pathogens. The specific receptors that recognize various components of the pathogens trigger signals that result in the production of proinflammatory cytokines as well as the activation of antigen-presenting cells, which activate the adaptive immune system. The discovery of the Toll-like receptors (TLRs) as important components of pathogen recognition has brought new understanding of the key signaling molecules involves in innate immune activation. Interestingly, it appears that most TLRs can recognize self-ligands as well and that mechanisms are required to discriminate between self and non-self ligands. One of these mechanisms is the expression of all the nucleic acid-specific TLR in endosomal compartments and not on the cell surface. Inappropriate activation of TLRs by self-components can result in sterile inflammation or autoimmunity. For example, TLR7 and TLR9 activation by endogenous RNA and DNA, transported to the endosomes in the form of immune complexes or non-covalently associated with cationic peptides, could be an important mechanism involved in promoting diseases such as systemic lupus erythematosus and psoriasis. In this review, we discuss the rationale for self-recognition by TLR7 and TLR9 as an important part of the development of lupus and other autoimmune diseases. We describe novel inhibitors of these receptors and provide evidence to support their use as novel therapeutic agents for autoimmunity.


Asunto(s)
Lupus Eritematoso Sistémico/tratamiento farmacológico , Receptores Toll-Like/antagonistas & inhibidores , Receptores Toll-Like/inmunología , Animales , Presentación de Antígeno/efectos de los fármacos , Presentación de Antígeno/genética , Autoantígenos/inmunología , ADN/inmunología , ADN/metabolismo , Células Dendríticas/efectos de los fármacos , Células Dendríticas/inmunología , Secuencia Rica en GC/inmunología , Humanos , Inmunidad Innata , Inmunoterapia Activa , Lupus Eritematoso Sistémico/inmunología , Lupus Eritematoso Sistémico/fisiopatología , Ratones , Oligodesoxirribonucleótidos/inmunología , Oligodesoxirribonucleótidos/farmacología , ARN/inmunología , ARN/metabolismo , Transducción de Señal/efectos de los fármacos , Transducción de Señal/genética , Transducción de Señal/inmunología , Receptores Toll-Like/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA